Added to YB: 2025-03-25
Pitch date: 2025-03-21
ELEV [bullish]
Elevation Oncology, Inc.
+24.74%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Market Cap
$22.4M
Pitch Price
$0.29
Price Target
0.44 (+21%)
Dividend
N/A
EV/EBITDA
0.59
P/E
-0.47
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Elevation Oncology: Broken Biotech, Slightly Riskier
ELEV: Biotech co discontinuing EO-3021 after Phase 1, 70% layoffs. 2nd failed drug after seribantumab. $17MM mkt cap, cash to 2H 2026. Continuing EO-1022 (IND 2026). Kevin Tang owns 8%. $30MM loan adds risk. Likely cash+CVR offer incoming. Author owns shares.
Read full article (1 min)